As thalassemic patients are exposed to various degrees of iron overload, the present study aimed at determining the presence of oxidative stress in these patients either those with continued or discontinued deferoxamine treatment [Iron Chelating agent ]. The present work was carried out on 29 thalassemic patients: 15 with regular deferoxamine intake and 14 patients with discontinued deferoxamine treatment for at least three months. In addition, 15 healthy normal individuals were taken as control group. To all studied subjects the following was done, complete blood picture, Hb electrophoresis, serum bilirubin, serum aminotransferases, gamma glutamyl transpeptidase, serum iron,TIBC and ferritin, plasma vitamin E, Red blood cell glutathione and thiobarbituric acid reactive substances [TBAR s]. From the results of this study it can be concluded that thalassemic patients have increased oxidant stress evidenced by low plasma vitamin E, low RBCs glutathione and increased plasma TBARS due to iron overload state [high serum iron, high percent saturation and high serum ferritin]. Chelation of iron by deferoxamine decreases this stress by rendering excessive iron metabolically inactive. Antioxidant supplementation is highly recommended.